How to Get Lantus (Insulin Glargine) in Maryland

What Lantus Is and Why Maryland Patients Need Specific Access Steps

Insulin glargine is a long-acting basal insulin analog that works by producing a steady, peakless release of insulin over approximately 24 hours. The FDA approved the original Sanofi formulation (Lantus) in April 2000, and the agency's current prescribing label documents its indication for adults and pediatric patients aged 6 years and older with type 1 or type 2 diabetes [1]. A biosimilar, Basaglar (Eli Lilly), received FDA approval in 2015 and carries the same clinical indication [2].

Basal insulin remains a foundational therapy. The ORIGIN trial (N=12,537), published in the New England Journal of Medicine in 2012, found that insulin glargine titrated to a fasting glucose target of 95 mg/dL or less did not increase cardiovascular events compared with standard care over a median of 6.2 years (hazard ratio 1.02 to 95% CI 0.94 to 1.11) [3]. That cardiovascular-safety signal is why many clinicians feel comfortable initiating insulin glargine in patients who have established atherosclerotic cardiovascular disease, a common comorbidity in Maryland's aging diabetic population.

Maryland does not restrict insulin glargine to a specialist. Any licensed prescriber with prescriptive authority in the state may write the prescription. The access challenge is primarily administrative: insurance PA requirements, pharmacy stock, and, for new patients, obtaining the baseline labs that any responsible prescriber will want before setting an initial dose.

Who Can Prescribe Lantus in Maryland

Maryland grants prescriptive authority to multiple provider types. Physicians (MD, DO), nurse practitioners with full practice authority, and physician assistants with a supervising physician agreement may all write insulin glargine prescriptions [4]. Maryland NPs operate under full-practice authority after completing a 18-month collaborative agreement period as required by Maryland Code, Health Occupations Article, §8-302 [5].

Telehealth prescribing is explicitly permitted in Maryland. The Maryland Telehealth Program, administered under the Health Services Cost Review Commission framework, recognizes audio-video encounters as valid for initiating new prescriptions including controlled substances and insulin [6]. Insulin glargine is not a controlled substance, so the prescribing threshold is lower than for Schedule II medications.

The HealthRX prescriber-match framework for Maryland insulin glargine access assigns patients to one of three pathways based on clinical complexity:

• Pathway A (new type 2, no complications): Telehealth NP or PCP visit, A1C and fasting glucose only, same-day Rx.
• Pathway B (type 1 or established type 2 with CKD/CVD): Endocrinology or internal medicine via telehealth or in-person, CMP plus A1C required, CGM discussion recommended.
• Pathway C (pediatric, age 6 to 17): Pediatric endocrinology referral, in-person preferred, parental consent documentation required.

Required Labs Before a Lantus Prescription in Maryland

No federal or Maryland-specific statute mandates a specific lab panel before prescribing insulin glargine. In practice, however, every major diabetes guideline recommends baseline testing that any licensed prescriber will follow.

The American Diabetes Association's 2024 Standards of Care require documentation of A1C at diagnosis and at least twice yearly once glycemic targets are met [7]. An eGFR or serum creatinine is standard before initiating any insulin regimen because renal impairment prolongs insulin half-life and raises hypoglycemia risk [8]. The ADA's 2024 guidance specifically notes that "insulin doses may need to be reduced in patients with renal impairment" [7].

Expect your Maryland prescriber to order:

• A1C (baseline glycemic control; target <7.0% for most non-pregnant adults per ADA 2024 [7])
• Fasting plasma glucose (titration anchor; ORIGIN targeted <95 mg/dL [3])
• Comprehensive metabolic panel (creatinine, eGFR, electrolytes)
• TSH if type 1 is suspected (autoimmune thyroid disease co-occurs in 17 to 30% of type 1 patients [9])
• Urinary albumin-to-creatinine ratio for established type 2 patients per ADA nephropathy screening [7]

Most Maryland LabCorp and Quest Diagnostics locations can process these panels within 24 to 48 hours. Telehealth platforms typically send a digital lab order so you can complete the draw at a location convenient to you before or immediately after your video visit.

How to Get a Lantus Prescription Through Maryland Telehealth

Telehealth is the fastest route for most Maryland patients. Maryland law requires that the prescriber hold a valid Maryland license; patients do not need to be seen in person first for a new insulin prescription [6].

Step 1. Book a visit. Select a Maryland-licensed provider on a telehealth platform or a direct clinic portal. Confirm that the provider holds an active Maryland medical or NP license through the Maryland Board of Physicians license verification tool [10].

Step 2. Complete intake forms. Most platforms ask for your diabetes history, current medications, most recent A1C, and any CGM or blood glucose log data. Upload these before the visit.

Step 3. Attend the video visit (15 to 30 minutes). The prescriber will review your labs, set an initial dose (commonly 10 units at bedtime or 0.1 to 0.2 units/kg/day for type 2 patients per ADA dosing guidance [7]), and transmit the prescription electronically to your preferred Maryland pharmacy.

Step 4. Receive prescription and titration plan. Insulin glargine requires individualized titration. A common protocol used in the INSIGHT trial and referenced by the American Association of Clinical Endocrinology increases the dose by 2 units every 3 days until fasting glucose reaches 80 to 110 mg/dL [11].

Step 5. Pick up or receive the medication. Most Maryland retail pharmacies stock Lantus 100 U/mL SoloStar pens and vials. Allow 24 hours for pharmacy processing. Mail-order pharmacies may take 3 to 5 additional business days on first fills.

Transferring an Existing Lantus Prescription to Maryland

Patients moving to Maryland from another state can transfer an existing insulin glargine prescription. Maryland pharmacies accept out-of-state transfers for non-controlled substances, provided the original prescriber holds an active license in the originating state and the prescription has remaining refills [12].

To transfer:

1. Call your preferred Maryland pharmacy with the name and phone number of your current pharmacy.
2. The Maryland pharmacist contacts the out-of-state pharmacy and verifies the prescription.
3. If the prescription requires a Maryland prescriber for ongoing refills (common after 12 months), schedule a telehealth or in-person follow-up to establish care before the supply runs out.

One practical point: if your current prescription is written for Lantus by brand name with "dispense as written," a Maryland pharmacist cannot substitute Basaglar without a new prescription. Ask your new Maryland provider whether the biosimilar is acceptable; it is therapeutically equivalent and often less expensive.

Lantus Pharmacy Access in Maryland

Maryland has over 1,200 licensed retail pharmacies, including major chains (CVS, Walgreens, Rite Aid, Giant Food Pharmacy) and independent pharmacies [12]. Insulin glargine 100 U/mL is widely stocked. Toujeo (insulin glargine 300 U/mL) and Basaglar may require 24-hour special orders at smaller independents.

503A compounding pharmacies in Maryland are licensed by the Maryland Board of Pharmacy and may compound insulin glargine preparations when a prescriber documents a patient-specific need not met by a commercially available product (for example, a concentration adjustment for pediatric dosing) [13]. The FDA's guidance on 503A compounding specifies that compounded insulin must be prepared from USP-grade bulk insulin glargine and requires a valid patient-specific prescription [14].

Mail-order and specialty pharmacies. Maryland Medicaid managed care organizations and most commercial plans contract with mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) for 90-day insulin supplies at lower cost-sharing. For patients who qualify for the Sanofi Insulins Valyou Savings Program, out-of-pocket cost for Lantus may be capped at $99 per month regardless of insurance status.

Cash-pay prices. Without insurance, a 10-mL vial of Lantus 100 U/mL averages $280 to $320 at Maryland retail pharmacies as of mid-2025. Basaglar biosimilar runs approximately 15 to 20% less. GoodRx coupons at Maryland pharmacies can reduce Basaglar to approximately $100 to $140 per vial at select locations.

Maryland Medicaid Prior Authorization for Lantus

Maryland Medicaid (HealthChoice) covers insulin glargine for both type 1 and type 2 diabetes, but prior authorization is required [15]. The PA process is managed by the enrollee's managed care organization (MCO), such as Aetna Better Health of Maryland, Amerigroup Maryland, or CareFirst Community Health Plan Maryland.

Standard PA documentation requirements include:

• Confirmed diagnosis of type 1 or type 2 diabetes (ICD-10 code E10.x or E11.x)
• Documentation of A1C value (typically >7.5% for initial PA approval)
• Evidence that the patient has tried or has a contraindication to NPH insulin (for type 2 patients) because NPH is the preferred formulary basal insulin in many Maryland Medicaid MCOs
• Prescriber's clinical justification if requesting brand Lantus over biosimilar Basaglar

The typical PA turnaround under Maryland Medicaid regulations is 72 hours for standard requests and 24 hours for urgent requests [15]. Denials may be appealed; the prescriber can submit a peer-to-peer review request, and if that fails, a formal grievance through the MCO's appeals process.

For commercial insurance in Maryland, PA requirements vary by plan. UnitedHealthcare and Aetna commercial plans in Maryland typically require a step-therapy edit, meaning the patient must document a trial of NPH or Basaglar before approving Lantus. A prescriber attestation that biosimilar substitution is clinically inappropriate (for example, due to hypoglycemia history with NPH) bypasses the step-therapy requirement in most cases under Maryland's step-therapy override law, which aligns with the national standard established under the 21st Century Cures Act [16].

Dosing Overview: What Your Prescriber Will Discuss

Insulin glargine is dosed once daily at any consistent time of day. The FDA-approved labeling for Lantus states that the starting dose for insulin-naive type 2 patients is 0.2 units/kg/day or 10 units once daily, whichever is lower, titrated to a fasting glucose target [1]. For type 1 patients, total daily insulin is split: approximately 40 to 50% is given as basal insulin glargine and the remainder as mealtime rapid-acting insulin [7].

The EDITION clinical trial program, which evaluated Toujeo (insulin glargine 300 U/mL) across more than 3,500 patients in phases 3a and 3b, showed that the 300 U/mL formulation produced a 21% lower rate of any hypoglycemic event compared with 100 U/mL at 6 months (P<0.001) [17]. This difference matters for patients with hypoglycemia unawareness, which affects approximately 20 to 25% of people with type 1 diabetes [18].

Key titration anchor points discussed in the ADA's 2024 Standards:

• Fasting glucose target: 80 to 130 mg/dL for most non-pregnant adults [7]
• Increase dose by 2 units every 3 days if fasting glucose consistently exceeds 130 mg/dL
• Reduce dose by 10 to 20% if fasting glucose is <80 mg/dL on two consecutive mornings

Storage, Administration, and Safety Points for Maryland Patients

Lantus vials and pens in-use may be kept at room temperature (below 86 degrees Fahrenheit) for up to 28 days [1]. Unopened stock must be refrigerated at 36 to 46 degrees Fahrenheit. Maryland summers regularly push ambient temperatures above 86 degrees, so patients should carry an insulin cooling case during outdoor activities from June through September.

Injection sites should be rotated within the same anatomical region (abdomen, thigh, or upper arm) to prevent lipohystrophy. The American Diabetes Association recommends abdomen injection for fastest absorption, though glargine's flat pharmacokinetic profile makes site-to-site variation less clinically significant than with rapid-acting insulins [7].

The most common adverse effect is hypoglycemia. In the ORIGIN trial, 1.00 severe hypoglycemic events per 100 patient-years occurred in the glargine group versus 0.31 in the standard-care group [3]. Patients should keep 15 to 20 grams of fast-acting carbohydrate (4 glucose tablets or 4 oz of juice) accessible at all times during titration. Maryland law under COMAR 10.09.80 permits school nurses to administer glucagon to students without a standing order, which is relevant for pediatric patients [19].

Cost Assistance Programs Available to Maryland Residents

Several assistance pathways reduce out-of-pocket cost for Maryland patients:

Sanofi Valyou Savings Program. Eligible patients pay no more than $99 per month for Sanofi insulins, including Lantus. Income documentation is not required for the capped copay tier.

Lilly Insulin Value Program. Basaglar biosimilar costs $35 per month for eligible patients through the Lilly program, available regardless of insurance status.

Maryland Pharmacy Assistance Program (MPAP). MPAP provides subsidized medications to Maryland residents aged 65 and older with income at or below 300% of the federal poverty level [20]. Insulin glargine is on the MPAP covered drug list.

340B pricing. Federally qualified health centers (FQHCs) in Maryland, including Chase Brexton Health Care and Choptank Community Health, dispense insulin at 340B contract pricing, which can reduce cash cost of Lantus to approximately $35 to $55 per vial [21].

Patient Assistance Program (PAP). Sanofi's Insulins PAP provides free Lantus to uninsured or underinsured patients with household income below 400% of the federal poverty level. The application is submitted by the prescriber on the patient's behalf.